Literature DB >> 22678524

A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney.

Ryoichi Imamura1, Yoshitaka Isaka, Ruben M Sandoval, Naotsugu Ichimaru, Toyofumi Abe, Masayoshi Okumi, Koji Yazawa, Harumi Kitamura, Jyunya Kaimori, Norio Nonomura, Hiromi Rakugi, Bruce A Molitoris, Shiro Takahara.   

Abstract

BACKGROUND: The tissue-protective effects of erythropoietin (EPO) have been extensively investigated, and EPO administration can raise the hemoglobin (Hb) concentration. Recently, we reported that carbamylated erythropoietin (CEPO) protected kidneys from ischemia-reperfusion injury as well as EPO.
METHODS: To investigate the clinical applications of CEPO, we next evaluated the long-term therapeutic effect of CEPO using a tubulointerstitial model rat. We randomized remnant kidney model rats to receive saline, EPO, or CEPO for 8 weeks.
RESULTS: CEPO- and EPO-treated rats had improved serum creatinine levels compared with saline-treated remnant kidney model rats, although the Hb level was significantly increased in EPO-treated rats. Two-photon microscopy revealed that EPO/CEPO significantly ameliorated tubular epithelial cell damage assessed by endocytosis. In addition, CEPO or EPO protected endothelial cells with a sustained blood flow rate. EPO or CEPO suppressed the number of TUNEL-positive apoptotic cells with weak αSMA staining. Furthermore, PCR analysis demonstrated that TGF-β and type I collagen expression was attenuated in EPO- or CEPO-treated rats, accompanied by a significant decrease in interstitial fibrosis.
CONCLUSION: We established a long-term therapeutic approach to protect tubulointerstitial injury with CEPO, and thus, the therapeutic value of this approach warrants further attention and preclinical studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678524      PMCID: PMC4108904          DOI: 10.1007/s10157-012-0647-x

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  26 in total

Review 1.  Intravital multiphoton microscopy of dynamic renal processes.

Authors:  Bruce A Molitoris; Ruben M Sandoval
Journal:  Am J Physiol Renal Physiol       Date:  2005-06

Review 2.  Emerging biological roles for erythropoietin in the nervous system.

Authors:  Michael Brines; Anthony Cerami
Journal:  Nat Rev Neurosci       Date:  2005-06       Impact factor: 34.870

Review 3.  Pleiotropic renal actions of erythropoietin.

Authors:  Prabal K Chatterjee
Journal:  Lancet       Date:  2005 May 28-Jun 3       Impact factor: 79.321

Review 4.  Anemia management and chronic renal failure progression.

Authors:  Jerome Rossert; Marc Froissart; Christian Jacquot
Journal:  Kidney Int Suppl       Date:  2005-12       Impact factor: 10.545

5.  Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system.

Authors:  L L Wu; A Cox; C J Roe; M Dziadek; M E Cooper; R E Gilbert
Journal:  Kidney Int       Date:  1997-05       Impact factor: 10.612

6.  A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury.

Authors:  Fabio Fiordaliso; Stefano Chimenti; Lidia Staszewsky; Antonio Bai; Eleonora Carlo; Ivan Cuccovillo; Mirko Doni; Manuela Mengozzi; Rossella Tonelli; Pietro Ghezzi; Thomas Coleman; Michael Brines; Anthony Cerami; Roberto Latini
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-25       Impact factor: 11.205

7.  Derivatives of erythropoietin that are tissue protective but not erythropoietic.

Authors:  Marcel Leist; Pietro Ghezzi; Giovanni Grasso; Roberto Bianchi; Pia Villa; Maddalena Fratelli; Costanza Savino; Marina Bianchi; Jacob Nielsen; Jens Gerwien; Pekka Kallunki; Anna Kirstine Larsen; Lone Helboe; Søren Christensen; Lars O Pedersen; Mette Nielsen; Lars Torup; Thomas Sager; Alessandra Sfacteria; Serhat Erbayraktar; Zubeyde Erbayraktar; Necati Gokmen; Osman Yilmaz; Carla Cerami-Hand; Qiao-Wen Xie; Thomas Coleman; Anthony Cerami; Michael Brines
Journal:  Science       Date:  2004-07-09       Impact factor: 47.728

8.  Erythropoietin protects against ischaemic acute renal injury.

Authors:  David A Vesey; Catherine Cheung; Betty Pat; Zoltan Endre; Glenda Gobé; David W Johnson
Journal:  Nephrol Dial Transplant       Date:  2004-02       Impact factor: 5.992

9.  Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.

Authors:  Michael Brines; Giovanni Grasso; Fabio Fiordaliso; Alessandra Sfacteria; Pietro Ghezzi; Maddalena Fratelli; Roberto Latini; Qiao-Wen Xie; John Smart; Chiao-Ju Su-Rick; Eileen Pobre; Deborah Diaz; Daniel Gomez; Carla Hand; Thomas Coleman; Anthony Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-29       Impact factor: 11.205

10.  Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure.

Authors:  Ferdinand H Bahlmann; Rong Song; Sascha M Boehm; Michael Mengel; Reinhard von Wasielewski; Carsten Lindschau; Torsten Kirsch; Kirsten de Groot; Robert Laudeley; Eva Niemczyk; Faikah Güler; Jan Menne; Hermann Haller; Danilo Fliser
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

View more
  8 in total

1.  Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-β and high glucose.

Authors:  Wentao Luo; Liumei Hu; Weiye Li; Guotong Xu; Linxinyu Xu; Conghui Zhang; Fang Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-23       Impact factor: 3.117

Review 2.  Mechanisms and consequences of carbamoylation.

Authors:  Sigurd Delanghe; Joris R Delanghe; Reinhart Speeckaert; Wim Van Biesen; Marijn M Speeckaert
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

3.  Finding the bottom and using it: Offsets and sensitivity in the detection of low intensity values in vivo with 2-photon microscopy.

Authors:  Ruben M Sandoval; Exing Wang; Bruce A Molitoris
Journal:  Intravital       Date:  2014-03-01

4.  Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models.

Authors:  Florian E Tögel; Jon D Ahlstrom; Ying Yang; Zhuma Hu; Ping Zhang; Christof Westenfelder
Journal:  J Am Soc Nephrol       Date:  2016-03-16       Impact factor: 10.121

5.  Human CD133+ Renal Progenitor Cells Induce Erythropoietin Production and Limit Fibrosis After Acute Tubular Injury.

Authors:  Shikhar Aggarwal; Cristina Grange; Corinne Iampietro; Giovanni Camussi; Benedetta Bussolati
Journal:  Sci Rep       Date:  2016-11-17       Impact factor: 4.379

6.  Carbamylated erythropoietin attenuates cardiomyopathy via PI3K/Akt activation in rats with diabetic cardiomyopathy.

Authors:  Hongying He; Xiaoyu Qiao; Suisheng Wu
Journal:  Exp Ther Med       Date:  2013-05-31       Impact factor: 2.447

7.  Renoprotective and neuroprotective effects of enteric hydrogen generation from Si-based agent.

Authors:  Yuki Kobayashi; Ryoichi Imamura; Yoshihisa Koyama; Makoto Kondo; Hikaru Kobayashi; Norio Nonomura; Shoichi Shimada
Journal:  Sci Rep       Date:  2020-04-03       Impact factor: 4.379

Review 8.  Advances in Understanding the Effects of Erythropoietin on Renal Fibrosis.

Authors:  Yangyang Zhang; Xiaoyu Zhu; Xiu Huang; Xuejiao Wei; Dan Zhao; Lili Jiang; Xiaoxia Zhao; Yujun Du
Journal:  Front Med (Lausanne)       Date:  2020-02-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.